Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort

Competing Interest Statement

TKK has consulted for Quanterix Corp., has received honoraria from the NIH for study section membership, and honoraria for speaker/grant review engagements from UPENN, UW-Madison, Advent Health, Brain Health conference, Barcelona-Pittsburgh conference and CQDM Canada, all outside of the submitted work. TKK has received blood biomarker data on defined research cohorts from Janssen and Alamar Biosciences for independent analysis and publication, with no financial incentive and/or research funding included. TKK is an inventor on patent #WO2020193500A1 and patent applications #2450702-2, #63/693,956, #63/679,361, and 63/672,952. XZ and YC are listed inventors on the University of Pittsburgh provisional patent #63/672,952. The other authors report no conflict of interest.

Funding Statement

The HCP study is funded by R01AG072641. TKK and the Karikari Laboratory were supported by the NIH (R01AG083874, U24AG082930, P30AG066468, RF1AG052525, R01AG053952, R37AG023651, RF1AG025516, R01AG073267, R01AG075336, R01AG072641, P01AG025204) and a professorial endowment from the Department of Psychiatry, University of Pittsburgh.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants provided written consent, and the University of Pittsburgh Institutional Review Board approved the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes